FOLD - Amicus earns a new bull at BTIG on prospects of Pompe disease candidate

Hailshadow/iStock via Getty Images Citing expert opinion on the company’s experimental therapy for Pompe disease, BTIG has assumed a buy rating on Amicus Therapeutics ([[FOLD]] +0.3%). In February, the company failed to meet the primary endpoint in a Phase 3 trial for AT-GAA (cipaglucosidase alfa and miglustat) in the treatment of late-onset Pompe disease ((LOPD)). However, citing a KOL, the analysts Yun Zhong and Xu Zou point out that the difference of forced vital capacity, which reached statistical significance, could be a more relevant efficacy endpoint in Pompe disease. With rolling submission for marketing application complete, a favorable FDA decision on AT-GAA is likely, wrote the analysts noting the FDA approval based on a similar data set for currently available standard-of-care, enzyme replacement therapy ((ERT)). BTIG has a price target of $15.00 per share on Amicus, implying a premium of ~$63.00 to the previous close. Despite the trial setback, Cantor

For further details see:

Amicus earns a new bull at BTIG on prospects of Pompe disease candidate